The stock of Lifecore Biomedical Inc (LFCR) has seen a -2.31% decrease in the past week, with a 17.03% gain in the past month, and a 11.67% flourish in the past quarter. The volatility ratio for the week is 3.56%, and the volatility levels for the past 30 days are at 3.81% for LFCR. The simple moving average for the past 20 days is 9.18% for LFCR’s stock, with a 25.74% simple moving average for the past 200 days.
Is It Worth Investing in Lifecore Biomedical Inc (NASDAQ: LFCR) Right Now?
The stock has a 36-month beta value of 0.67. Opinions on the stock are mixed, with 2 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for LFCR is 32.67M, and at present, short sellers hold a 7.03% of that float. On July 04, 2025, the average trading volume of LFCR was 270.20K shares.
LFCR stock’s latest price update
The stock of Lifecore Biomedical Inc (NASDAQ: LFCR) has decreased by 0.00% when compared to last closing price of $8.04.Despite this, the company has seen a loss of -2.31% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-17 that NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/LFCR.
Analysts’ Opinion of LFCR
Craig Hallum, on the other hand, stated in their research note that they expect to see LFCR reach a price target of $8. The rating they have provided for LFCR stocks is “Buy” according to the report published on September 05th, 2024.
Stephens gave a rating of “Equal-Weight” to LFCR, setting the target price at $2 in the report published on March 20th of the previous year.
LFCR Trading at 14.78% from the 50-Day Moving Average
After a stumble in the market that brought LFCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.84% of loss for the given period.
Volatility was left at 3.81%, however, over the last 30 days, the volatility rate increased by 3.56%, as shares surge +16.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.10% upper at present.
During the last 5 trading sessions, LFCR fell by -2.31%, which changed the moving average for the period of 200-days by +55.21% in comparison to the 20-day moving average, which settled at $7.36. In addition, Lifecore Biomedical Inc saw 70.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LFCR starting from English Aron R., who sold 1,139,504 shares at the price of $6.50 back on May 27 ’25. After this action, English Aron R. now owns 414,599 shares of Lifecore Biomedical Inc, valued at $7,411,562 using the latest closing price.
English Aron R., the 10% Owner of Lifecore Biomedical Inc, sale 150,419 shares at $7.12 during a trade that took place back on May 28 ’25, which means that English Aron R. is holding 264,180 shares at $1,071,555 based on the most recent closing price.
Stock Fundamentals for LFCR
Current profitability levels for the company are sitting at:
- -0.15% for the present operating margin
- 0.33% for the gross margin
The net margin for Lifecore Biomedical Inc stands at -0.34%. The total capital return value is set at -0.1%. Equity return is now at value -83.58%, with -18.46% for asset returns.
Based on Lifecore Biomedical Inc (LFCR), the company’s capital structure generated 0.98 points at debt to capital in total, while cash flow to debt ratio is standing at 0.02. The debt to equity ratio resting at 58.48. The interest coverage ratio of the stock is -0.89.
Currently, EBITDA for the company is 35.6 million with net debt to EBITDA at -11.37. When we switch over and look at the enterprise to sales, we see a ratio of 3.24. The receivables turnover for the company is 6.73for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.71.
Conclusion
To sum up, Lifecore Biomedical Inc (LFCR) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
